<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Korean Med Sci</journal-id>
      <journal-id journal-id-type="pmc">jkms</journal-id>
      <journal-title>Journal of Korean Medical Science</journal-title>
      <issn pub-type="ppub">1011-8934</issn>
      <issn pub-type="epub">1598-6357</issn>
      <publisher>
        <publisher-name>Korean Academy of Medical Sciences</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">10102531</article-id>
      <article-id pub-id-type="pmc">3054166</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Behenoyl cytarabine-associated reversible encephalopathy in a patient with acute myelogenous leukemia.</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Cho</surname>
            <given-names>S. G.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Moon</surname>
            <given-names>H.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>J. H.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>S. Y.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>C. C.</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>K. S.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <aff>Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul.</aff>
      <pub-date pub-type="ppub">
        <month>2</month>
        <year>1999</year>
      </pub-date>
      <volume>14</volume>
      <issue>1</issue>
      <fpage>89</fpage>
      <lpage>92</lpage>
      <abstract>
        <p>We report a case of reversible encephalopathy syndrome in a 16-year-old girl with acute myelogenous leukemia (AML), who is undergoing during consolidation chemotherapy composed of BH-AC (N4-behenoyl-1-beta-D-arabinofuranosyl cytosine) and idarubicin. On the 6th day of chemotherapy, she was in a drowsy state following generalized tonic clonic seizure lasting 20 minutes. MR images revealed extensive cortical and subcortical white matter brain edema. Alertness returned over the 24 hr following by the discontinuation of BH-AC and intravenous administration of diphenylhydantoin, although she complained of intermittent headaches and visual disturbance. She gradually recovered from these symptoms during subsequent 7 days. Previously noted abnormal signal intensities have nearly disappreared on follow-up MRI obtained on the 22nd day after the first seizure. She was discharged without any neurologic sequela. This case suggests that BH-AC, a derivative of cytosine arabinoside (1-beta-D-arabinofuranosylcytosine) could be a cause of reversible encephalopathy syndrome.</p>
      </abstract>
    </article-meta>
  </front>
</article>
</pmc-articleset>
